[go: up one dir, main page]

WO2018155979A1 - Nanovésicule dérivée de cellules souches, et composition favorisant et restaurant la pousse des cheveux la contenant - Google Patents

Nanovésicule dérivée de cellules souches, et composition favorisant et restaurant la pousse des cheveux la contenant Download PDF

Info

Publication number
WO2018155979A1
WO2018155979A1 PCT/KR2018/002333 KR2018002333W WO2018155979A1 WO 2018155979 A1 WO2018155979 A1 WO 2018155979A1 KR 2018002333 W KR2018002333 W KR 2018002333W WO 2018155979 A1 WO2018155979 A1 WO 2018155979A1
Authority
WO
WIPO (PCT)
Prior art keywords
nano
vesicles
hair
hair growth
promoting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/002333
Other languages
English (en)
Korean (ko)
Inventor
김홍중
구본준
김종근
하태경
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enhancedbio Inc
Original Assignee
Enhancedbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enhancedbio Inc filed Critical Enhancedbio Inc
Publication of WO2018155979A1 publication Critical patent/WO2018155979A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/82—Preparation or application process involves sonication or ultrasonication

Definitions

  • Stem cell-derived nano-vesicles and a composition for promoting hair growth and hair growth comprising the same
  • the present invention relates to a stem cell-derived nano-vesicles and a composition for promoting hair growth and hair growth comprising the same, and more specifically, a) passing the stem cells through a filter; b) centrifuging the cell solution passed through the filter in step a) to obtain nano-vesicles; c) separating and purifying the uniform size of the nano-vesicles from the nano-vesicles obtained in step b); And d) a method comprising the step of encapsulating the hair growth promoting component in the nano vesicles separated and purified in step c), for hair loss treatment or hair growth and hair growth promotion comprising the stem cell-derived nano vesicles as an active ingredient. It relates to cosmetic compositions and pharmaceutical compositions.
  • Mesenchymal enjoyment cells are cells that have the ability to differentiate into various mesenchymal tissues while maintaining sel f-renewal and stem cell maintenance. It has been found to synthesize materials for regeneration.
  • mesenchymal stem cells show immune regulation by inhibiting part of the immune system, inhibiting the activity and proliferation of T and B lymphocytes, preventing the activity of NK cel l, avoiding CTL-mediated lysi s, and dendritic cells. It is capable of coordinating the substances secreted by (dendr it ic cel l) or macrophage (al lo ⁇ transplantat ion) or xenotransplantation (xeno-1 r ansp 1 ant at i on) ° ll It is known to be usable.
  • mesenchymal stem cells were first identified in the bone marrow by Fr iedenstein et al. In 1966, it has been confirmed that they can differentiate into chondrocytes, bone cells, and muscle cells. There is a lot of research on this. In addition, mesenchymal stem cells are currently found in addition to bone marrow, adipose tissue, cord blood cord blood, synovial membrane, synovial fizid, periosteum, dermis, trabecular bone, muscle, etc., each with a similar phenotype However, there are various differences in the proliferation and differentiation potential.
  • alopecia alopecia areata (AA), which is usually repairable to microinflammatory and called local alopecia, and alopecia associated with chemotherapy or radiation therapy (ie, secondary alopecia).
  • Drug remedies are generally used to address these hair loss.
  • Various drugs such as vitamins and hormones, have been tried, and hair growth agents commercially available under the trade name "Minoxidil” described in US Pat. Nos. 3, 461,461 and 4,596, 812 are mainly used.
  • the effects of a commercially available product as a hair growth or hair loss preventing agent on the hair include hair growth stage induction effect, hair growth stage extension effect, 5 ⁇ -reductase inhibitory effect, blood circulation promoting effect, bactericidal effect, anti dandruff effect, moisturizing effect, antioxidant
  • the effects such as conventional hair loss prevention, hair growth promoting effect is not well divided.
  • the components for promoting hair growth are not effectively delivered to the body, and hair loss prevention or hair growth promoting effects are not sufficiently exhibited.
  • the present inventors have completed the present invention by finding a method for more effectively delivering drugs into the body, separating nanovesicles from stem cells, and effectively delivering therapeutic or functional substances using the same. Therefore, the object of the present invention a) passing the stem cells through the filter;
  • step b) centrifuging the cell solution through the filter in step a) (ul tracentr i fuge) to obtain nano-vesicles;
  • d) prepared by the method comprising the step of encapsulating the components for promoting hair growth in nano-vesicles separated and purified in step c), hair loss prevention or hair growth and cosmetics for promoting hair growth and hair growth comprising a stem cell-derived nano-vesicles as an active ingredient
  • a composition It is also an object of the present invention to provide a cosmetic composition for the prevention of hair loss or hair growth and hair growth is composed of the vesicle-derived nano-vesicles prepared by the above method. It is also an object of the present invention to provide a cosmetic composition for hair loss prevention or hair growth and hair growth promotion consisting essentially of the stem cell-derived nano-vesicles prepared by the above method. Another object of the present invention
  • step b) centrifuging the cell solution passed through the filter in step a) (ul tracentr i fuge) to obtain nano-vesicles;
  • hair loss treatment or hair growth and hair growth promoting pharmaceutics comprising the stem cell-derived nano vesicles as an active ingredient prepared by the method comprising the step of encapsulating the components for promoting hair growth in the nano-vesicles separated and purified in step c).
  • a composition It is also another object of the present invention is to provide a hair treatment or hair growth and hair growth, the pharmaceutical compositions for promoting the body consisting of stem cells derived from nano-vesicles prepared by the above method.
  • Another object of the present invention is to provide a pharmaceutical composition for treating hair loss or promoting hair growth and hair growth consisting essentially of the stem cell-derived nano-vesicles prepared by the above method. Another object of the present invention to provide a use of stem cell-derived nano-vesicles prepared by the following method for the treatment of hair loss or hair growth and hair growth promoting agent will be:
  • step b) centrifuging the cell solution passed through the filter in step a) (ul tracentr i fuge) to obtain nano-vesicles;
  • Another object of the present invention is to provide a method for treating hair loss or hair growth and hair growth, characterized in that the effective amount of the stem cell-derived nano-vesicles prepared by the following method is administered to a subject in need thereof.
  • step b) centrifuging the cell solution passed through the filter in step a) (ul tracentr i fuge) to obtain nano-vesicles;
  • step c) encapsulating the component for promoting hair growth in the nano-vesicles separated and purified in step c).
  • step b) centrifuging the cell solution passed through the filter in step a) (ul tracentri fuge) to obtain nano-vesicles;
  • step d) hair loss prevention or hair growth and hair growth promoting cosmetics prepared by the method comprising the step of encapsulating the components for promoting hair growth in the nano-vesicles separated and purified in step c) as an active ingredient.
  • the composition is provided.
  • the present invention provides a cosmetic composition for preventing hair loss or hair growth and hair growth is composed of the stem cell-derived nano-vesicles prepared by the above method.
  • the present invention provides a cosmetic composition for hair loss prevention or hair growth and hair growth promotion consisting essentially of the stem cell-derived nano-vesicles prepared by the above method.
  • step b) centrifuging the cell solution passed through the filter in step a) to obtain nano-vesicles
  • step c) hair loss treatment or hair growth and hair growth promoting pharmaceutics comprising the stem cell-derived nano vesicles as an active ingredient prepared by a method comprising the step of encapsulating the components for promoting hair growth in the nano-vesicles separated and purified in step c).
  • the present invention provides a pharmaceutical composition for treating hair loss or hair growth and hair growth comprising the stem cell-derived nano-vesicles prepared by the above method.
  • the present invention provides a pharmaceutical composition for hair loss treatment or hair growth and hair growth promotion consisting essentially of the cell-derived nano-vesicles prepared by the above method.
  • the present invention provides a use of stem cell-derived nano-vesicles prepared by the following method for the preparation of a hair growth treatment or hair growth and hair growth promoting agent:
  • step b) centrifuging the cell solution through the filter in step a) to obtain nano-vesicles
  • the present invention provides a method for treating hair loss or hair growth and hair growth, characterized in that for administering an effective amount of the stem cell-derived nano-vesicles prepared by the following method to a subject in need thereof:
  • step a) passing the stem cells through the filter; b) centrifuging the cell solution passed through the filter in step a) to obtain nano-vesicles;
  • step c) encapsulating the component for promoting hair growth in the nano-vesicles separated and purified in step c).
  • step b) centrifuging the cell solution passed through the filter in step a) to obtain nano-vesicles
  • step d) prepared by the method comprising the step of encapsulating the components for promoting hair growth in nano-vesicles separated and purified in step c), hair loss prevention or hair growth and cosmetics for promoting hair growth and hair growth comprising a stem cell-derived nano-vesicles as an active ingredient To provide a composition.
  • the present invention provides a cosmetic composition for preventing hair loss or hair growth and hair growth is composed of the stem cell-derived nano-vesicles prepared by the above method.
  • the present invention provides a cosmetic composition for hair loss prevention or hair growth and hair growth promotion consisting essentially of the stem cell-derived nano-vesicles prepared by the above method.
  • Step (a) is characterized in that to pass the stem cells to the filter.
  • the stem cells cultured in serum-free medium are passed through the stem cells three times or more through a filter having a size of ⁇ .
  • 'Stem cells' of the present invention include any undifferentiated or partially undifferentiated cell having the ability to proliferate (self-renewal) and differentiate (plastic). These stem cells are characterized by specific cell lineage (1 ineage), an end-point cell during development. Replaces cells.
  • Stem cells also include stem cells with unlimited self-renewal and pluripotency plasticity and progenitor cells with multipotent or unipotency plasticity.
  • the stem cells in the present invention is characterized in that the mesenchymal stem cells, preferably may be mesenchymal stem cells derived from brain, liver, lung, umbilical cord blood, fetal blood, kidney, adipose tissue, placenta, amniotic membrane or bone marrow have.
  • 'Mesenchymal Stem Cells (MSCs)' is often referred to as mesenchymal stromal cells and refers to pluripotent undifferentiated cells.
  • Mesenchymal stem cells have non-homogeneous populations of stem cells with the ability to self-renewal and mesoderm lineage and different embryonic lineages such as endoderm and ectoderm.
  • Mesenchymal stem cells can differentiate into various types of cells including osteoblasts, chondrocytes, adipocytes, and the like.
  • mesenchymal stem cells Embryonic stem cells (ESCs), induced Pluri otent Stem Cells (iPSCs) and other tissue-specific stem cells, compared with other tissue-specific stem cells, tissue regeneration, blood production assistance ( 1 111 01) 01 ⁇ It is an ideal candidate for the clinical application of regenerative medicine because of its wide availability, low ethical issues and immunogenicity, including support and immunomodulation.
  • Mesenchymal stem cells can be isolated from brain, liver, lung, fetal blood, umbilical cord blood, kidney, adipose tissue and placenta. Preferably it may be isolated from human bone marrow.
  • Step b) is characterized in that to obtain a nano-vesicle by centrifugation (ultracentrifuge) the cell solution passed through the filter.
  • the stem cells are suspended in PBS, passed through the ⁇ size filter and 5 ⁇ polycarbonate filter, and then subjected to ultracentrifugation, to obtain nano-vesicles (Example 2-1 and See FIG. 1).
  • the step (c) is of a uniform size in the nano-vesicle obtained in the step (b) It is characterized by separating and purifying the nano-vesicles.
  • the 'nanovesi cle' of the present invention refers to a vesicle structure having a nano unit size, and is distinguished from nano liposomes consisting of lipid bilayers in terms of being surrounded by a lipid monolayer, It has a structure in which the inside and the outside of the nanovesicle is separated by a lipid bilayer composed of cell membrane components, and has cell membrane lipids, cell membrane proteins, nucleic acids, and cellular components. It effectively contains biomaterials that are difficult to synthesize artificially and can be delivered to specific tissues through membrane proteins, and mediates the transport of mRNA, miRNA and proteins between cells, and plays an important role in signal transduction and interaction between cells.
  • Nanovesicles also represent heterogeneous populat ions, depending on the cell from which they are derived, the number of cells, the size of the cells, and the composition of the antigen. More preferably, it may be a nano-vesicle having a size of 50 to 200nm.
  • the nano-vesicles in order to separate and purify the nano-vesicles, were separated by using a density gradient method, which is a method of ultracentrifugation after adding 50% euprip and 10% Opti-Prap and removing nuclear material. The nano vesicles having a certain quality were separated and purified (see Example 2-3).
  • Step d) is characterized in that to encapsulate the hair growth promoting component in the nano-vesicles separated and purified in step c).
  • 'hair loss' refers to a phenomenon in which hair falls off the scalp or a condition in which the hair is genital or thin
  • 'promoting hair growth' means not only promoting the production of new hair, but also allowing the existing hair to grow healthy.
  • Another term used in the art has the same meaning as wool or hair growth promotion.
  • 'hair growth promoting ingredient' is an insulin-like growth factor (IGF-1), fibroblast growth factor ( ⁇ -f ibroblast growth factor, ⁇ -FGF), thymosin P 4 (thymosin ⁇ 4), biotin and vitamin C.
  • the 'insulin-like growth factor (IGF-1)' is a hormone having a structure similar to insulin, and is a hair follicle growth-promoting factor produced by DHT (Dihydrotestosterone). It plays an important role in pediatric growth and continues to function in adults to maintain body maintenance.
  • the 'fibroblast growth factor ( ⁇ -F ibroblast growth factor, ⁇ -FGF)' is a growth factor that stimulates fibroblasts to induce strong proliferation, pituitary gland, brain, kidney, adrenal gland, placenta, bone matrix, cartilage, It is widely distributed in endothelial cells and fibroblasts. It stimulates fibroblasts located in the dermis, promotes repair of damaged tissues and collagen synthesis, making the scalp healthy and preventing hair loss.
  • the thymosin p 4 is a 4.9 kDa in vivo protein, and regulates cell migration to promote cell migration, thereby causing vascular endothelial cell migration and wound healing. It is a protein involved in angiogenesis, wound healing, hair growth, and cancer metastasis by promoting the movement of cells, hair source cells and / or cancer cells.
  • the biotin (Biot in) is a kind of vitamin B complex required for the growth of animals and plants and is known as a hair nutrient for helping hair loss treatment and prevention, and has a coenzyme donation to make keratin protein, which makes hair healthy. .
  • the 'vitamin C' has the effect of preventing hair loss by inhibiting the hair follicle destruction substance, and has the effect of thickening thin hair by promoting collagen synthesis.
  • the method for encapsulating the hair growth promoting component in the nano-vesicles may use a well-known encapsulation technique.
  • an osmotic pressure method, an ultrasonic grinding method, an electrophoretic method may be used, and most preferably an ultrasonic grinding method. It is possible to encapsulate the hair growth promoting component using.
  • Encapsulation in the present invention means that the desired drug is encapsulated into the nano-vesicles while substantially maintaining physical properties such as structure and size of the nano-vesicles.
  • the structure of the nano-vesicles separated and purified in step c) Or to maintain physical properties such as size, in order to more efficiently enclose the component for promoting hair growth, to separate the purified nano-vesicles in the component solution for promoting hair growth, and to incubate for 2 hours in a 37 ° C incubator , Ultrasonic The method of grinding (soni cat ion) (40kHz, 40 ° C, 1 hour), the electrophoresis method (200V) was carried out, respectively, and then the filling rate of each solution was measured and compared.
  • the cosmetics are hair tonic, hair lotion, hair cream, hair spray, hair mousse, hair gel, hair conditioner, hair shampoo, hair rinse, hair pack, hair treatment, eyebrow hair agent, eyelash hair restorer, eyelash nutrient, pet It is characterized in that the animal shampoo or pet rinse.
  • the formulation of the cosmetic composition of the present invention is not particularly limited and may be appropriately selected as desired.
  • the cosmetic composition of the present invention may be prepared in a formulation such as skin external ointment, flexible cosmetics, nourishing cosmetics, nutrition cream, massage cream, essence, pack, emulsion dog, oil gel and the like.
  • the skin external ointment may contain petrolatum, polyoxyethylene oleyl ether phosphate, etc., in addition to the medicinal extract of the present invention, the flexible cosmetics, in addition to the medicinal extract of the present invention, polyhydric alcohols (propylene glycol, glycerin, etc.) ) And surfactants (polyethylene oleyl ether, polyoxyethylene, hardened castor oil, etc.) and the like.
  • the nutrient cream and nutrition cream may include oils (squalene, petrolatum, octyldodecanol, etc.) and wax components (stearyl alcohol, beeswax, etc.) in addition to the medicinal extract of the present invention, the essence is in addition to the composition of the present invention
  • oils such as glycerin and propylene glycol
  • the massage cream may include oils such as liquid paraffin, vaseline, isononylisononanoate, and the pack or general emulsified cosmetics may be used in addition to the medicinal extracts of the present invention.
  • the cosmetic composition of the present invention in addition to the components described above in each formulation, water, oil, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, or fragrances, etc. It can mix and use suitably as needed.
  • the present invention in addition to the components described above in each formulation, water, oil, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, or fragrances, etc. It can mix and use suitably as needed.
  • the present invention in addition to the components described above in each formulation, water, oil, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, or fragrances, etc. It can mix and use suitably as needed.
  • the present invention in addition to the components described above in each formulation, water, oil, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, or fragrances, etc. It can
  • step b) centrifuging the cell solution passed through the filter in step a) to obtain nano-vesicles
  • step c) hair loss treatment or hair growth and hair growth promoting pharmaceutics comprising the stem cell-derived nano vesicles as an active ingredient prepared by the method comprising the step of encapsulating the components for promoting hair growth in the nano-vesicles separated and purified in step c).
  • the present invention provides a pharmaceutical composition for treating hair loss or hair growth and hair growth comprising the stem cell-derived nano-vesicles prepared by the above method.
  • the present invention also provides a pharmaceutical composition for hair loss treatment or hair growth and hair growth is composed essentially of the stem cell-derived nano-vesicles prepared by the above method.
  • the pharmaceutical composition according to the present invention may contain a stem cell-derived nano-vesicles alone or may be formulated in a suitable form with a pharmaceutically acceptable carrier, and may further contain a sibling or a diluent.
  • 'pharmaceutically acceptable' refers to a non-toxic composition that is physiologically acceptable and does not cause allergic reactions such as gastrointestinal disorders, dizziness, or the like when administered to humans.
  • Pharmaceutically acceptable carriers may further include, for example, carriers for oral administration or carriers for parenteral administration.
  • Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. In addition, it may include various drug delivery materials used for oral administration to the peptide formulation.
  • carriers for parenteral administration may include water, suitable oils, saline, aqueous glucose, glycols, and the like, and may further include stabilizers and preservatives. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol.
  • the pharmaceutical composition of the present invention may further include a lubricant wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent and the like in addition to the above components.
  • a lubricant wetting agent e.g., a talc, a kaolin, a kaolin, a sulfate, a sulfate, a sulfate, sulfate, g., sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, a sorbitol, a sorbitol, a sulfate, a sulfate, a sulfate, a sulfate, a sulfate,
  • Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual, or rectal administration.
  • the pharmaceutical composition of the present invention may be formulated into a preparation for oral or parenteral administration according to the route of administration as described above.
  • compositions of the present invention are formulated using powders, granules, tablets, pills, sugar tablets, capsules, liquids, gels, syrups, slurries, suspensions, etc. using methods known in the art.
  • oral formulations can obtain tablets or tablets of sugars by combining the active ingredients with solid brothers and then grinding them, adding suitable auxiliaries and processing them into granular mixtures.
  • suitable excipients include sugars and corn starch, wheat starch, rice starch and potato starch, including lactose, textrose, sucrose, solbi, manny, xili, erythritol and malty.
  • Layering agents such as saloses, gelatin, polyvinylpyrrolidone, and the like, including starch, salose, methyl salose, sodium carboxymethylcellose and hydroxypropylmethyl-cellulose.
  • crosslinked polyvinylpyridone, agar, alginic acid or sodium alginate may be added as a disintegrant.
  • the pharmaceutical composition of the present invention may further include an anticoagulant, a lubricant, a humectant, a fragrance emulsifier, and a preservative.
  • Formulations for parenteral administration may be formulated by methods known in the art in the form of injections, creams, lotions, external ointments, oils, humectants, gels, aerosols and nasal inhalants. These formulations are described in Remington's Pharmaceutical Science, 19th ed., Mack Publishing Company, East on, PA, 1995, a prescription generally known in all pharmaceutical chemistries.
  • the total effective amount of the composition of the present invention may be administered to a patient in a single dose and may be administered by a long term administered multiple dose protocol in a single ion dose treatment protocol. have.
  • Pharmaceutical of the Invention The composition may vary the content of the active ingredient depending on the extent of the disease.
  • the preferred total dose of the pharmaceutical composition of the present invention may be from about 0.01 «g to 10,000 mg, most preferably 0.1 / g to 500 mg per kg of patient body weight per day.
  • the pharmaceutical composition and dose are determined by taking into consideration the various factors such as the age, weight, health condition, sex, severity of the disease, diet and excretion rate, as well as the formulation method, route of administration and frequency of treatment. In view of this, one of ordinary skill in the art will be able to determine the appropriate effective dosage of the compositions of the present invention.
  • the pharmaceutical composition according to the present invention is not particularly limited to its formulation, route of administration and method of administration as long as the effect of the present invention is shown.
  • the jaw of the back of the mouse is removed, and then divided into three groups, each group of 5 ml of PBS, minoxidil 3% or stem cell-derived endoplasmic reticulum solution, respectively, once a day for 2 weeks.
  • each group of 5 ml of PBS, minoxidil 3% or stem cell-derived endoplasmic reticulum solution respectively, once a day for 2 weeks.
  • the hair growth effect was the best in the group coated with the stem cell-derived nano-vesicle solution prepared in the present invention (see Example 4 and FIG. 3).
  • the present invention provides the use of the stem cell-derived nano-vesicles prepared by the following method for the preparation of a hair growth or hair growth and hair growth promoting agent:
  • step b) centrifuging the cell solution passed through the filter in step a) to obtain nano-vesicles
  • the present invention provides a method for treating hair loss or hair growth and hair growth, characterized by administering an effective amount of the stem cell-derived nano-vesicles prepared by the following method to a subject in need thereof.
  • step b) centrifuging the cell solution passed through the filter in step a) to obtain nano-vesicles; c) separating and purifying the uniform size of the nano-vesicles from the nano-vesicles obtained in step b);
  • the term 'effective amount' of the present invention when administered to a subject, refers to an amount of improving or treating, preventing, detecting, diagnosing, or inhibiting a disease caused by hair loss, and a condition showing an effect of inhibiting or reducing disease caused by hair loss.
  • it may be a mammal, especially an animal including a human, and may be a cell, tissue, organ or the like derived from the animal.
  • the subject may be a patient in need of the effect.
  • treatment' of the present invention refers generically to ameliorating a disease caused by hair loss or a symptom of a disease caused by hair loss, which may include treating, substantially preventing, or ameliorating such a disease. It may include, but is not limited to, alleviating, healing or preventing one or most of the symptoms resulting from the disease caused by hair loss.
  • the term 'compri sing' of the present invention is used in the same way as 'containing' or 'with features', and in the composition or method, additional component elements or method steps not mentioned are used. Do not exclude The term 'consi sting of' means to exclude additional elements, steps or components, etc., unless otherwise specified.
  • essentialt ial ly consi st ing of' includes, in the scope of a composition or method, a component element or step described, as well as a component element or step that does not substantially affect its basic properties, and the like. Means that.
  • the present invention provides a composition for promoting hair growth and hair growth comprising nano-vesicles derived from stem cells.
  • the method of the present invention prevents hair loss.
  • the hair growth and hair growth promoting effect has the effect of treating or ameliorating the hair loss symptoms, it can be usefully used in the manufacture of cosmetics and therapeutics exhibiting hair growth and hair growth promoting effect.
  • La and lb shows a schematic diagram of a method for producing mesenchymal cell-derived nano-vesicles.
  • Figure 2a is a graph showing the size distribution of the nano-vesicles obtained by passing the mesenchymal stem cells through the filter, followed by ultracentrifugation.
  • Figure 2b shows the observation of the morphology of mesenchymal stem cell-derived nano-vesicles using a TEM microscope.
  • Figure 3 shows that the stem cell-derived nano-vesicles containing the hair growth component to the mouse to confirm the hair growth efficacy.
  • frozen cells were cultured using DMEM / FBS culture medium until reaching 80% confluency under 5% C0 2 conditions, and then StemPro, MesenCul t, Xmedi a, 10 ml of Nutr iStem and MSCGM-CD were added and seeded in a T75 flask (f lask) that had been coated before use with a coating reagent for each medium, referring to the protoc of each medium.
  • the medium was identified to maintain the lowest PDT value constantly, and the cell viability was checked for each passage to maintain 80% or more. It was confirmed.
  • a filter having a hole of ⁇ ⁇ size was put in a filter support of a specially designed centrifuge bottle (bott le), and then assembled with a main body and washed with alcohol and PBS. Then, 5xl0 7 eel ls / ml of cultured fungal cells was suspended in 1 ml PBS (phosphate buf fered sal ine) solution. After the suspension was injected into the body, ultracentrifugation was performed for 1 minute and 45 seconds at 13000 g, and repeated three times under the same conditions.
  • PBS phosphate buf fered sal ine
  • Example 2-1 In order to measure the size of the nano-vesicles prepared in Example 2-1 and to analyze the characteristics were carried out as follows.
  • the protein contained in the nano-vesicles obtained in Example 2-1 was distilled in lml PBS at a concentration of 5 yg / ml, placed in a cuvette, and then subjected to a dynamic light scattering particle size analyzer. (Marvern Zetasi zer Nano).
  • the size of the nano-vesicles was confirmed to be 25 to 100nm, it was confirmed that the average size is about 50nm.
  • the nano-vesicle solution suspended in PBS was added to a glow-discharged carbon-coated copper grid (3) Adsorbed for a minute. The grid was then washed with distilled water and then stained with 2% uranlacetate for 1 minute.
  • TEM microscope, JEMlOlUeol, Japan was used to observe the nano endoplasmic reticulum using a transmission electron microscope.
  • the stem cell-derived nano-vesicles could be confirmed that the phospholipid consisting of a middle layer, it was confirmed that the spherical form.
  • the stem cell-derived nano-vesicles of the present invention was spherical, consisting of a phospholipid bilayer, it could be confirmed that having an average size of 50nm.
  • nanovesicles were separated and purified by the following method.
  • the cell suspension is passed through a 5 ⁇ polycarbonate filter washed with alcohol and PBS as in the above example. Then, add 50 ⁇ l Optiprap, 400 ⁇ l of 10% Optiprep and 1 ml of the suspension through the filter into 2.2 ml ultracentr i fuge tube, respectively, for 1 hour at 100, 000 g. Ultracentrifugation was performed during the process. After centrifugation, nanovesicles were obtained in the layer between 50% Optiprep and 10% Doptoprap.
  • nano-vesicles having a certain quality were separated and purified by removing more than 90% of the nuclear material.
  • IGF-1, ⁇ -FGF, Thymosin ⁇ 4, Biotin, and Vitamin C were selected as the hair growth components to be administered to the nanovesicles.
  • 50-200 nm nano-vesicles ltng / ml were dispensed in PBS, 1) incubation for 2 hours in a 37 ° C. incubator, 2) sonication for 1 hour in an ultrasonic bath (40 kHz, 40 ° C) (sonication), 3) electrophoresis (200V) three processes were performed.
  • mice C57BL / 6 mice were purchased, and the experiments were carried out at 7 weeks of age, with adaptation for 1 week at 25 ° C and 40% humidity. Mice were placed in a desiccator containing ether and anesthetized for 1 minute, and the back of the mouse was removed using a hair remover and classified into three groups. One day later, PBS, 3% minoxidil, and stem cell-derived endoplasmic reticulum solutions were applied to mice without back wounds. Each sample was applied 5ml once a day for 2 weeks, after 3 days, 7 days, 14 days after the change of the hair growth of the mouse was observed. PBS was used as a control group, and minoxidil, which was previously used for hair loss treatment, was used to compare effects.
  • the stem cell-derived nano-vesicles containing the hair growth promoting component of the present invention has a remarkable effect on hair growth promotion and hair loss treatment.
  • the method of the present invention has the effect of treating or improving hair loss symptoms through hair loss prevention, hair growth and hair growth promoting effects, and through this, to prepare cosmetics and therapeutic agents exhibiting hair growth and hair growth promoting effects. It can be useful.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une microvésicule dérivée de cellules souches et une composition favorisant la pousse des cheveux la contenant et, plus spécifiquement, une composition cosmétique et une composition pharmaceutique, qui sont destinées à traiter la chute des cheveux ou à favoriser la croissance des cheveux et qui contiennent, en tant que principe actif, une nanovésicule dérivée de cellules souches préparée par un procédé comprenant les étapes consistant à : (a) suspendre, dans une solution isotonique, une solution de culture de cellules souches et un ingrédient favorisant la croissance des cheveux ; (b) dégrader les cellules dans la solution de l'étape (a) ; et (c) obtenir une nanovésicule par ultracentrifugation de la solution de l'étape (b). Le procédé de la présente invention a pour effet de traiter ou de soulager des symptômes de chute de cheveux par l'intermédiaire de la prévention de la chute de cheveux et d'effets favorisant la pousse des cheveux, ce qui le rend utile dans la préparation de produits cosmétiques et d'agents thérapeutiques qui présentent des effets favorisant la pousse des cheveux.
PCT/KR2018/002333 2017-02-24 2018-02-26 Nanovésicule dérivée de cellules souches, et composition favorisant et restaurant la pousse des cheveux la contenant Ceased WO2018155979A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170024992 2017-02-24
KR10-2017-0024992 2017-02-24

Publications (1)

Publication Number Publication Date
WO2018155979A1 true WO2018155979A1 (fr) 2018-08-30

Family

ID=63253856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/002333 Ceased WO2018155979A1 (fr) 2017-02-24 2018-02-26 Nanovésicule dérivée de cellules souches, et composition favorisant et restaurant la pousse des cheveux la contenant

Country Status (2)

Country Link
KR (1) KR20180098475A (fr)
WO (1) WO2018155979A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117224464A (zh) * 2023-08-24 2023-12-15 广东科标生物科技有限公司 一种用于美白和抗皮肤衰老的间充质干细胞仿生囊泡复合物及其制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102368442B1 (ko) * 2021-02-19 2022-02-28 주식회사 엑소코바이오 생리활성이 강화된 엑소좀의 생산방법 및 이의 응용

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010049428A (ko) * 1999-05-27 2001-06-15 차알스 제이. 메츠 신규 국소 제형
KR20110002443A (ko) * 2009-07-01 2011-01-07 주식회사이언메딕스 포유류의 유핵세포에서 유래된 마이크로베시클 및 이의 용도
US20150024011A1 (en) * 2010-10-18 2015-01-22 Agency For Science, Technololgy And Research (A*Star) Use of exosomes to promote or enhance hair growth
KR20160086253A (ko) * 2015-01-08 2016-07-19 한양대학교 에리카산학협력단 줄기세포로부터 추출된 엑소좀을 함유하는 피부 미백, 주름개선 또는 재생용 화장료 조성물
KR20170020244A (ko) * 2015-08-12 2017-02-22 (주)프로스테믹스 줄기세포의 분화 촉진 및 세포의 증식 촉진용 조성물과 그 제조방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010049428A (ko) * 1999-05-27 2001-06-15 차알스 제이. 메츠 신규 국소 제형
KR20110002443A (ko) * 2009-07-01 2011-01-07 주식회사이언메딕스 포유류의 유핵세포에서 유래된 마이크로베시클 및 이의 용도
US20150024011A1 (en) * 2010-10-18 2015-01-22 Agency For Science, Technololgy And Research (A*Star) Use of exosomes to promote or enhance hair growth
KR20160086253A (ko) * 2015-01-08 2016-07-19 한양대학교 에리카산학협력단 줄기세포로부터 추출된 엑소좀을 함유하는 피부 미백, 주름개선 또는 재생용 화장료 조성물
KR20170020244A (ko) * 2015-08-12 2017-02-22 (주)프로스테믹스 줄기세포의 분화 촉진 및 세포의 증식 촉진용 조성물과 그 제조방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117224464A (zh) * 2023-08-24 2023-12-15 广东科标生物科技有限公司 一种用于美白和抗皮肤衰老的间充质干细胞仿生囊泡复合物及其制备方法和应用

Also Published As

Publication number Publication date
KR20180098475A (ko) 2018-09-04

Similar Documents

Publication Publication Date Title
JP6847080B2 (ja) 皮膚美白またはしわ改善用組成物
JP6970459B2 (ja) 脂肪由来幹細胞由来のエキソソームを有効成分として含む組成物の皮膚炎の改善の用途
EP2745840B1 (fr) Composition comprenant des microvésicules issues de cellules souches pour utilisation pour favoriser la neurogenèse
JP7741559B2 (ja) 細胞外小胞及びその皮膚製品における使用
KR101793899B1 (ko) 성체 줄기세포와 분화된 세포의 혼합 배양액 및 이의 용도
JP6353073B2 (ja) 細胞回復のための組成物並びにその作製及び使用方法
EP3981871A1 (fr) Composition pour favoriser la production d'exosomes dérivés de cellules souches et renforcer le caractère-souche
CN110123838B (zh) 负载白藜芦醇的人多能干细胞外泌体及其制备方法与用途
CN110869033A (zh) 包含干细胞来源外排体作为有效成分的组合物用于预防或减轻瘙痒的用途
CN113876687B (zh) 一种改善肌肤生理特性的活性肽与胎盘干细胞外泌体在药品或化妆品中的应用
EP3744347A1 (fr) Composition pour une utilisation dans le traitement de maladies cutanées
CN105132369A (zh) 一种将间充质干细胞转化为睾酮分泌细胞的诱导剂及诱导培养基
WO2018155979A1 (fr) Nanovésicule dérivée de cellules souches, et composition favorisant et restaurant la pousse des cheveux la contenant
CN113952362A (zh) 诱导性细胞外囊泡在制备延长哺乳动物寿命或治疗或预防衰老制剂中的应用
JP2018057301A (ja) 幹細胞の未分化状態維持剤及び増殖促進剤
CN120603599A (zh) 包含干细胞来源的外泌体的用于治疗或预防脱发的组合物及其制备方法
JP2018057302A (ja) 幹細胞の未分化状態維持剤及び増殖促進剤
JP6615589B2 (ja) 幹細胞の未分化状態維持剤及び増殖促進剤
JP6587899B2 (ja) 幹細胞の未分化状態維持剤及び増殖促進剤
JP2017108671A (ja) 幹細胞の未分化状態維持剤及び増殖促進剤
CN109674972A (zh) 月桃精油的应用
JP6649050B2 (ja) 幹細胞の未分化状態維持剤及び増殖促進剤
JP7453705B2 (ja) エキソソーム及びその調製プロセス及びその使用
JP7205880B2 (ja) メラノサイト分化誘導促進剤及びその使用方法
CN111182886A (zh) 包含皂苷元和外排体作为有效成分的组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18758490

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18758490

Country of ref document: EP

Kind code of ref document: A1